Results 281 to 290 of about 29,580 (292)

Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream

Journal of Allergy and Clinical Immunology, 2020
Michael D Howell
exaly  

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2020
Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio   +2 more
exaly  

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study

Lancet Haematology,the, 2020
Jean-Jacques Kiladjian, Pierre B Zachée, Tamas Masszi   +2 more
exaly  

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine, 2012
Claire N Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-ali   +2 more
exaly  

Ruxolitinib

Reactions Weekly
  +5 more sources

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

Lancet Haematology,the, 2019
Moshe Talpaz, Philip S Boonstra, Ryan A Wilcox   +2 more
exaly  

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

New England Journal of Medicine, 2015
Alessandro Maria Vannucchi, Martin Griesshammer, Tamas Masszi   +2 more
exaly  

Ruxolitinib‐associated infections: A systematic review and meta‐analysis

American Journal of Hematology, 2018
Federico Lussana, Marco Cattaneo, Alessandro Rambaldi   +2 more
exaly  

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia, 2016
exaly  

Ruxolitinib

Reactions Weekly, 2013
openaire   +2 more sources